Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 18, 2022 08:00 ET | Source: Avadel Pharmaceuticals plc

Avadel Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference

DUBLIN, Ireland, May 18, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that...
May 09, 2022 07:00 ET | Source: Avadel Pharmaceuticals plc

Avadel Pharmaceuticals Provides Corporate Update and Reports First Quarter 2022 Financial Results

FDA review of NDA for FT218 continues; launch readiness preparations on-track to support potential commercial launch Presented interim results from ongoing RESTORE open-label extension / switch...
May 02, 2022 08:00 ET | Source: Avadel Pharmaceuticals plc

Avadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter Financial Results on May 9

DUBLIN, Ireland, May 02, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it...
April 26, 2022 07:30 ET | Source: Avadel Pharmaceuticals plc

Avadel Pharmaceuticals Provides Comment on Recent Trading Activity

DUBLIN, Ireland, April 26, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today provided a...
April 25, 2022 08:00 ET | Source: Avadel Pharmaceuticals plc

Avadel Pharmaceuticals Announces Interim Data from the Open-Label RESTORE Study at the 2022 American Academy of Neurology Annual Meeting

Results from patient preference questionnaire indicate that people with narcolepsy preferred the once-nightly over the twice-nightly dosing regimen for oxybatesNocturnal adverse event questionnaires...
April 06, 2022 08:00 ET | Source: Avadel Pharmaceuticals plc

Avadel Pharmaceuticals Announces Publication of Positive Secondary Endpoint Data from Pivotal Phase 3 REST-ON Trial

Once-at-bedtime FT218 demonstrated clinically meaningful improvement in assessments of disrupted nighttime sleep compared to placebo in adults with narcolepsyNew data bolster positive primary endpoint...
March 22, 2022 08:00 ET | Source: Avadel Pharmaceuticals plc

Avadel Pharmaceuticals to Present at Upcoming Investor Conferences

DUBLIN, Ireland, March 22, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, announced today that Greg Divis, Chief...
March 17, 2022 07:00 ET | Source: Avadel Pharmaceuticals plc

Avadel Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results

FDA review of NDA for FT218 is ongoing; commercial and launch preparations on-track to support potential commercial launch Expanded the robust portfolio of data supporting the potential impact of...
March 14, 2022 16:30 ET | Source: Avadel Pharmaceuticals plc

Avadel Pharmaceuticals Announces Appointment of Brandi Robinson as Senior Vice President, Corporate Affairs

DUBLIN, Ireland, March 14, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced the appointment of...
March 14, 2022 08:00 ET | Source: Avadel Pharmaceuticals plc

Avadel Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full Year 2021 Financial Results on March 17th

DUBLIN, Ireland, March 14, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, announced today that it will host a...